The ability to suppress wild type p53-independent apoptosis may play an important role in the oncogenicity of p53 mutant proteins. However, structural elements necessary for this activity are unknown. Furthermore, it is unclear whether this mutant p53 mediated inhibition is speci®c to the apoptotic pathway or a more general suppression of the cellular response to stress. We observed that an unmodi®ed C-terminus was required for the suppression of apoptosis by the p53 135(Ala to Val) oncogenic p53 mutant. It was also required for the novel activity of G 2 arrest suppression, the predominant response at low levels of genotoxic stress. These observations are consistent with a model whereby mutant p53 suppressive activity is not speci®c to the apoptotic pathway, but rather increases the threshold of genotoxic stress needed for a DNA damage response to occur. Furthermore, these observations indicate that it may be possible to selectively kill mutant p53 expressing cells based on the lower sensitivity of their growth arrest response. Oncogene (2001) 20, 4891 ± 4898.
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The p53 tumor suppressor gene responds to cellular stress such as DNA damage through initiating temporary growth arrest and DNA repair, permanent growth arrest, terminal dierentiation, or apoptosis, depending on cell type, the nature of the stress, and its degree (Ko and Prives, 1996; Levine, 1997; Zhao et al., 2000) . It is mutated in over 50% of human cancers and 74% of these mutations are missense, which result in the expression of full length, albeit mutant, p53 proteins. This fraction of missense mutations is much higher than in other tumor suppresser genes (Hussain and Harris, 1998) , and implies that p53 mutant proteins confer some selective advantage in carcinogenesis. About three quarters of missense mutations occur in the DNA binding core domain of p53, where they often occur in one of six hotspots (Hussain and Harris, 1998) . Such missense mutants may lose wild type p53 function. In addition, some exhibit oncogenic activity (reviewed in Sigal and Rotter, 2000) . This oncogenic activity is partly the result of mutant p53 interference with the function of the remaining wild type p53 protein by a oligomerization domain dependent dominant negative mechanism (Chene, 1998; Kern et al., 1992; Milner and Medcalf, 1991; Shaulian et al., 1992; Srivastava et al., 1993; Unger et al., 1993) . However, even in the absence of wild type p53, p53 mutant proteins have oncogenic eects. This gain of function includes increased tumorigenicity (Dittmer et al., 1993; Hsiao et al., 1994; Lanyi et al., 1998; Wolf et al., 1984) , increased mutation frequency following irradiation (Iwamoto et al., 1996) , genomic instability , augmented metastatic potential (Crook and Vousden, 1992; Hsiao et al., 1994) , interference with dierentiation (Shaulsky et al., 1991) , suppression of apoptosis Li et al., 1998; Murphy et al., 2000; Peled et al., 1996) , and enhanced long term survival .
The importance of functional regions outside the DNA binding core domain tends to be conserved between wild type and mutant p53. Thus, the Nterminal transactivation domain (Frazier et al., 1998; Lin et al., 1995) , the oligomerization domain (Chene, 1998; Unger et al., 1993) , and the main nuclear localization signal (Shaulsky et al., 1990) , exhibit similar functions in both proteins. The role of the extreme C-terminus (approximately the last 30 residues) in the gain of oncogenic function of p53 mutants is less clear. In wild type p53, the extreme C-terminus has a negative regulatory function that keeps nonactivated wild type p53 in its cryptic form until its inhibition is removed by post-translational modi®ca-tions during activation (Anderson et al., 1997; Gu and Roeder, 1997; Hupp and Lane, 1994; Hupp et al., 1992 Hupp et al., , 1995 Marston et al., 1998; Mundt et al., 1997; Wolkowicz et al., 1998) . Surprisingly therefore, the C terminus of the wild type p53, encoded by the regular spliced p53 mRNA, plays a positive role in the induction of apoptosis (Almog et al., 1997 (Almog et al., , 2000 . When the extreme C-terminus of p53 mutants was modi®ed, some oncogenic p53 mutants regained DNA binding to wild type p53 speci®c elements, and some even regained the ability to transactivate wild type p53 target genes (for review see Selivanova et al., 1998) . When the extreme C-terminus was truncated in the murine p53 135(Ala to Val) mutant, this protein Figure 1 A regular C-terminus is necessary for the p53 Val 135(Ala to Val) mediated suppression of apoptosis induced by genotoxic stress. Clones were generated from murine p53 null M1/2 myeloid cells infected with the vector pLXSN (control clone), and pLXSN with an insert containing either p53 135(Ala to Val) with a regularly spliced (RS) C-terminus (clones RS-53 and RS-61), or alternatively spliced (AS) C-terminus (clones AS-27 and AS-41). Clones were treated with the genotoxic agents cisplatin (Abic) or etoposide (Sigma), and apoptosis measured by the acridine orange (AO) assay for DNA condensation described previously for these cells (Li et al., 1998) . Brie¯y, cells were ®xed in 80% EtOH, and on the day of the assay incubated with RNase (Sigma) and treated with 0.1 M HCl. After 1 min, the acid denaturation was quenched by the addition of a solution of 90% citric acid, 10% Na 2 HPO 4 , and 0.06% acridine orange (Molecular Probes). Cells were analysed in a FACSort¯ow cytometer (Becton Dickinson) with an excitation wavelength of 488 nm. (a) shows a representative AO data set after 28 h at 378C with no treatment or 5 mg/ml cisplatin. Cells with condensed DNA are either apoptotic (circled in gray), or mitotic (circled in black). The percentage of apoptotic cells is indicated in the lower part of each plot. Upon cisplatin treatment, the mitotic population disappeared, and there was a sharp
The C-terminus is essential for mutant p53 gain of function A Sigal et al became reactive with PAb246 and PAb1620, core domain antibodies speci®c for the wild type conformation (Milner and Medcalf, 1991) . Functionally, truncation of the extreme C-terminus resulted in a loss of mutant p53 transactivation potential in the 281(Asp to Gly) mutant (Frazier et al., 1998) and truncation of a section that included the extreme C-terminus and the oligomerization domain led to decreased the tumorgenicity of this mutant (Lanyi et al., 1998) . p53 core domain mutants were found to interfere with p53-independent apoptosis induced by growth factor removal, serum starvation (Lassus et al., 1999) , the combination of HBV-X expression and TNF-a (Lee et al., 2000) , and various types of DNA damage in p53 null M1/2 myeloid and H1299 lung adenocarcinoma cells Li et al., 1998; Peled et al., 1996) . p53 mutants also interfered with apoptosis and growth suppression induced by p73 (Di Como et al., 1999; Marin et al., 2000; Strano et al., 2000) , which gives rise to the hypothesis that the mechanism behind mutant p53 gain of function is dominant negative inhibition of p53 family members. The oligomerization domains of p53 and p73 have been shown not to associate (Davison et al., 1999) , though binding does occur through the DNA binding domains (Strano et al., 2000) .
In this study we characterized a novel activity of the p53 135(Ala to Val) oncogenic mutant, the desensitization of cells to G 2 arrest induction, which required a concentration of etoposide two orders of magnitude lower than apoptosis. We observed that at high levels of genotoxic stress, expression of the p53 135(Ala to Val) mutant downgraded the DNA damage response from apoptosis to G 2 arrest, while it increased the threshold for G 2 arrest at low levels of genotoxic stress. Both eects of p53 135(Ala to Val) were dependent on an intact C-terminus. Thus, cells expressing mutant p53 may be protected against apoptosis at high levels of genotoxic stress. However, it may be possible to kill such cells based on their lack of growth arrest entry at low levels of genotoxic stress, by using agents that only damage cells when they enter mitosis.
The p53 135(Ala to Val) mutant raises the levels of genotoxic stress required to initiate the apoptotic response
To con®rm the ability of mutant p53 to interfere with wild type p53-independent apoptosis, we used the p53-null M1/2 murine myeloblastic cell line, retrovirally infected with the p53 135(Ala to Val) mutant (Almog increase in the apoptotic population. Cells expressing the p53 135(Ala to Val) mutant with an RS C-terminus were protected from the cisplatin induced apoptosis. To ensure clones expressed functional p53 135(Ala to Val), untreated cells were shifted to 328C, the permissive temperature for the wild type p53 conformation of this mutant, and apoptosis assayed by AO (b). After 36 h at 328C, clones expressing both AS and RS p53 135(Ala to Val) showed extensive apoptosis while the control clone remained unaected. Average+s.d. of three independent experiments. The role of the C-terminus in the suppression of apoptosis mediated by p53 135(Ala to Val) at 378C, the temperature permissive for the mutant conformation, was examined in (c). Clones RS-53 (&), RS-61 (X), AS-27 (~), AS-41 (*), and the control clone (&) were treated with cisplatin at concentrations of 0, 2.5, 5, and 10 mg/ml for 28 h or etoposide at concentrations of 0, 7.5, 15, and 30 mM for 38 h, and apoptosis assayed by AO. Clones that expressed p53 135(Ala to Val) with a regularly spliced C-terminus had a markedly lower apoptotic pro®le relative to the control clone, while clones expressing the AS form were similar in their response to the control. Average+s.d. of triplicates of independent representative experiments Figure 2 Alternative splicing of the C-terminus abolishes the apoptotic suppression mediated by p53 135(Ala to Val): analysis by Annexin-V. Clones RS-53, AS-27 and control were left untreated or treated with 30 mM etoposide for 24 h at 378C, and apoptosis was measured by staining un®xed cells with Annexin-V and propidium iodide (PI) as follows: cells were incubated in 10 mM HEPES pH 7.4, 140 mM NaCl, 5 mM CaCl 2 containing 2%¯uorescein labeled Annexin-V stock solution (Boehringer Mannheim), and PI was pulsed at a concentration of 4 mg/ml immediately before FACS analysis. The C-terminus is essential for mutant p53 gain of function A Sigal et al Figure 3 The p53 135(Ala to Val) mutant decreases the sensitivity of genotoxic stress responses. (a) apoptotic (hatched bars) and G 2 arrest responses (®lled bars) of clones treated at 378C with 0, 2.5, and 5 mg/ml cisplatin for 28 h or 0. 7.5, and 15 mM etoposide for 38 h, and assayed by AO. Each stacked bar represents the fraction of apoptotic and arrested cells in the same sample. Clones expressing RS p53 135(Ala to Val) undergo G 2 arrest, a response to lower levels of genotoxic stress at the expense of the apoptotic response. A representative experiment. Sensitivity of clones to G 2 arrest inducing levels of etoposide is shown in (b). Cells were treated with the concentrations of etoposide shown for 24 h and assayed by propidium iodide (Sigma) for DNA content. The sub G 1 apoptotic (Ap) and G 2 regions were gated as shown in the upper left plot. At these low levels of genotoxic stress after 24 h, G 2 arrest was the primary response and no increase in apoptosis was seen. At 100 nM etoposide, the G 2 arrest was well developed in both the control and AS-27, but not in RS-53. This growth arrest was also re¯ected in the cell numbers (c). Clones were seeded at a density of 5610 4 /ml and left untreated or treated with 100 nM etoposide for 68 h. Cell numbers after 68 h were estimated by counting, and their viability by Tryphan Blue (Sigma) exclusion. Total cells in untreated (®lled bars) and treated (striped bars) samples, and viable untreated (un®lled bars) and treated (hatched bars) samples are shown. The control and AS-27 underwent growth arrest after etoposide treatment, while RS-53 did not. Average+s.d. of six ®elds of a representative experiment et al., 1997). Stable clones were subjected to apoptosis inducing levels of genotoxic stress. We detected apoptosis based on its hallmark of DNA condensation measured by the acridine orange (AO) DNA binding dichromatic stain. After denaturation with weak acid, condensed DNA does not re-aneal and the single stranded DNA is detected by AO as a shift from green to red luminescence (Darzynkiewicz, 1994a,b) . Upon treatment with the chemotherapeutic agent cisplatin, which causes DNA damage by intrastrand and interstrand crosslinking, we observed that the control clone infected with the retroviral vector without the mutant p53 coding insert, exhibited more than twice the level of apoptosis relative to the clone that expressed the p53 135(Ala to Val) mutant ( Figure  1a ). This pattern was also con®rmed by the sub-G1 fractions obtained with propidium iodide (data not shown).
Having established the anti-apoptotic gain of function of the p53 135(Ala to Val) mutant, we now asked whether the extreme C-terminus was involved in this eect. As a model for extreme C-terminal modi®cation, we used an alternatively spliced (AS) form of p53, a naturally occurring murine modi®cation that changes the last 26 amino acids of the C-terminus relative to the regularly spliced (RS) form (Arai et al., 1986) . This modi®cation is similar in its eects in wild type p53 to the truncation of the C-terminus or modi®cation by the binding of C-terminal antibody PAb421 (Wolkowicz et al., 1995) . To exclude clonal variations, we used two clones expressing AS and RS p53 135(Ala to Val) in several assays. To ensure that the clones were indeed expressing p53 135(Ala to Val), we took advantage of the conformational sensitivity of this mutant to temperature. At 328C p53 135(Ala to Val) shifts to the wild type p53 conformation and cells expressing it enter apoptosis (Michalovitz et al., 1990) . Figure 1b shows that after 36 h at 328C, cells that expressed either the AS or RS forms of p53 135 (Ala to Val) underwent extensive apoptosis, while the control clone did not.
When we examined the level of cisplatin and etoposide induced apoptosis in clonal populations at the temperature permissive for the mutant conformation (378C), clones AS-27 and AS-41 which expressed AS p53 135(Ala to Val), had a similar apoptotic pro®le to the control clone and diered markedly from clones RS-53 and RS-61 which expressed the RS p53 135(Ala to Val) mutant (Figure 1c) . However, treatments with the highest concentrations of etoposide or cisplatin used resulted in high apoptotic levels in clones expressing RS p53 135(Ala to Val), and this was especially evident with cisplatin treatment at 10 mg/ml. Thus, RS p53 135(Ala to Val) did not completely block apoptosis, but rather increased the threshold of genotoxic stress needed to initiate it.
To con®rm that RS p53 135(Ala to Val) mediated suppression of apoptosis while AS p53 135(Ala to Val) did not, we used the Annexin-V assay. The results showed a similar pattern as obtained with AO, where the clone RS-53 exhibited a markedly lower proportion of apoptotic cells relative to the control or AS-27, while AS-27 did not dier from the control in its response (Figure 2a,b) .
The p53 135(Ala to Val) raises the threshold of genotoxic stress for the initiation of G 2 arrest
We next examined whether the p53 135(Ala to Val) mutant can interfere with other responses to DNA damage, or whether its interference is speci®c to the apoptotic pathway. One response distinct from apoptosis seen in this system is G 2 arrest. Cells not undergoing apoptosis were found mostly in G 2 after treatment with cisplatin or etoposide (Figure 3a) . Cells that expressed RS p53 135(Ala to Val) had lower apoptosis levels and higher G 2 arrest (Figure 3a) . To determine whether p53 135(Ala to Val) caused cells preferentially to enter G 2 arrest, we examined the sensitivity of cells to G 2 entry. We used low etoposide concentrations to obtain G 2 arrest, and propidium iodide staining as a measure of DNA content, where G 2 arrest was indicated by an increase in the number of cells having a DNA content of 4N (Figure 3b ). We Figure 4 Possible consequences of the decrease of genotoxic stress response sensitivity mediated by mutant p53. Mutant p53 expression causes increased thresholds of DNA damage for the initiation of either the growth arrest or apoptosis responses. Thus, at high levels of DNA damage mutant p53 expressing cells will enter growth arrest instead of apoptosis, and at low levels of DNA damage they will continue cycling instead of entering growth arrest. This predicts that they will continue to accumulate damage while cells without mutant p53 have arrested, initiated repair, and stopped damage accumulation, if the genotoxic agents are cell cycle dependent. If enough DNA damage is accumulated during this window of no response, it is possible that cells with mutant p53 will in the long-term growth arrest or die, while cells without mutant p53 will be less aected Oncogene The C-terminus is essential for mutant p53 gain of function A Sigal et al observed that G 2 arrest was the primary response at these low levels of genotoxic stress, as opposed to apoptosis which occurred at drug concentrations two orders of magnitude higher (compare etoposide concentrations in Figure 3b to Figures 1 and 2 ). At these low levels of genotoxic stress, no signi®cant increase in apoptosis (measured as cells with a sub-G 1 DNA content) was detected relative to untreated cells ( Figure  3b ). However, a pronounced G 2 arrest was observed. This arrest was reversible and cells that were treated with 100 nM etoposide for 68 h and then washed, were able to re-enter the cell cycle and showed no signs of impaired viability for the 2 weeks we observed them (data not shown). Clones AS-27 and the control showed a pronounced G 2 arrest after treatment with 100 nM etoposide, but RS-53 did not (Figure 3b ). These dierences gradually disappeared as progressively higher concentrations of etoposide were used (Figure 3b ). Clone RS-61 showed a similar pattern to clone RS-53 (data not shown). Thus, expression of the p53 135(Ala to Val) mutant caused a shift from an apoptotic to a growth arrest response, consistent with the cells recognizing apoptosis inducing levels of genotoxic stress as lower, growth arrest inducing levels. At low, growth arrest inducing levels of genotoxic stress, cells expressing p53 135(Ala to Val) did not arrest, indicating that the genotoxic stress signal given was below threshold for initiating the G 2 response in these cells. Signi®cantly, the clone expressing the AS p53 135(Ala to Val) mutant had a very similar response pro®le to the control (Figure 3b) , indicating that the Cterminus is necessary for this mutant p53 activity. To con®rm the presence of growth arrest after low etoposide treatment, we seeded clones at a density of 5610 4 /ml, and counted the number of cells present after 68 h of 100 nM etoposide treatment. We observed no signi®cant dierence between the number of cells of RS-53 with treatment versus without treatment, while the control clone and AS-27 clearly entered growth arrest after treatment (Figure 3c ). The arrest was less pronounced in clone AS-27 relative to the control, and matched the slightly lower G 2 entry of AS-27 at this etoposide concentration relative to control (Figure 3b) , indicative of some residual mutant p53 gain of function present in AS p53 135(Ala to Val).
The requirement for a regularly spliced C-terminus for mutant p53 gain of function activity is consistent with a role for this domain in the stabilization of the mutant conformation, previously shown as the appearance of wild type p53 epitopes with C-terminal truncation (Milner and Medcalf, 1991) . Based on evidence of the role of the extreme C-terminus as an allosteric negative regulatory domain in wild type p53, it has been proposed that oncogenic core domain mutations stabilize the contact that occurs between the DNA binding domain and the C-terminus in latent p53, so that this allosteric contact cannot be broken by post-translational modi®cations. Hence, activation of p53 mutant proteins cannot occur by the normal physiological mechanisms (Hupp et al., 1993; Selivanova et al., 1998) . Interestingly, wild type p53, when expressed at low levels, was shown to protect from apoptosis in a growth arrest independent manner. This protection from apoptosis was dependent on the presence of the last 38 amino acids of the C-terminus of human p53 (Lassus et al., 1996 (Lassus et al., , 1999 , perhaps hinting at some link between wild type p53 physiological activities and mutant p53 gain of function. The same group showed that DD, a p53 fragment with a D15-301 deletion that retains the oligomerization and the extreme C-terminus, can protect cells against apoptosis (Lassus et al., 1999) .
We observed that mutant p53 can interfere with the two discrete outcomes of DNA damage: apoptosis and growth arrest. Such inhibition can either occur on each pathway separately, or it can occur at a common initiation point. The latter possibility is more probable: if the probability of mutant p53 having one gain of function A is P A , where 05P51, then the probability of it having two independent functions B and C is P B 6P C . Since the probability of one given protein physiologically interacting with another given protein is small, all the P values here are small as well. Therefore, if the P values are not hugely dierent from each other, then P A 444P B 6P C . It can be argued that mutant p53 retains the wild type p53 ability to bind many targets, but this seems unlikely in the p53 135(Ala to Val) mutant due to the conformational shift.
Candidates for the initiation point of both growth arrest and apoptosis in cells lacking wild type p53 are p53 family members such as p73. p73 has been shown to induce apoptosis in response to DNA damage (Agami et al., 1999; Wang, 2000; Yuan et al., 1999) . Furthermore, p53 mutants have been shown to associate with p73 (Strano et al., 2000) and block p73 function (Di Como et al., 1999; Marin et al., 2000; Strano et al., 2000) . Since we observed that the Cterminus of the p53 135(Ala to Val) mutant is necessary for its gain of function, an indication of p73 involvement would be to examine whether the ability of mutant p53 to inhibit p73 depends on the mutant p53 C-terminus. In addition, p73 must be shown to mediate the wider spectrum of responses, such as apoptosis resulting from growth factor deprivation (Peled et al., 1996) and the combination of HBV-X expression and TNF-a (Lee et al., 2000) , which mutant p53 has been shown to inhibit. It was shown that the maintenance of G 2 arrest requires 14-3-3 (Chan et al., 1999) , and it would be interesting to examine whether mutant p53 can interfere with this eect.
Previously, it was observed that co-expression of mutant p53 protein, with wild type p53 protein, deregulates the control of the DNA-damage-dependent G 2 checkpoint (Aloni-Grinstein et al., 1995; Powell et al., 1995; Schwartz and Rotter, 1998) . Data presented here indicates that this may not, or not only, be the results of dominant negative inhibition of wild type p53.
The suppression of apoptosis and G 2 arrest by RS p53 135(Ala to Val) was not a total block, but an increase in the thresholds of genotoxic stress needed to
The C-terminus is essential for mutant p53 gain of function A Sigal et al initiate these responses. We propose that this shift upwards of both thresholds results in two windows being created relative to cells null for p53 (Figure 4 ). In one, cells that express mutant p53 experience sucient genotoxic stress to enter growth arrest but not apoptosis, and so are protected from apoptosis and in some cases from further genotoxic stress (see below). A second window occurs where the genotoxic stress is sub-threshold for growth arrest initiation for mutant p53 expressing cells but not p53 null cells. Growth arrest is expected to be protective against damaging agents such as etoposide (a topoisomerase II inhibitor, and therefore damages DNA during replication) and also has been shown to be anti-apoptotic by allowing time for DNA repair before mitosis entry (Chan et al., 1999; Zhou and Elledge, 2000) . The increased accumulation of DNA damage in cells expressing mutant p53 in the low genotoxic stress window may lead to several outcomes, depending on whether cells expressing p53 mutants are also more tolerant of genetic aberrations. If they are, then they will exit the growth arrest with more DNA lesions and their tumorgenicity will likely increase. If they have similarly stringent repair requirements as cells not expressing mutant p53 or if the amount of damage is not compatible with further growth, they will in the long term die or growth arrest while cells not expressing mutant p53 may recover. A chemotherapeutic approach can be devised that takes better advantage of the lack of G 2 arrest at low etoposide concentrations. This may involve ®rst arresting cells with low etoposide, and killing the cycling mutant p53 expressing cells with microtubule-active drugs such as paclitaxel or vinblastine. This approach has met with some success in dierentially killing cells that do not enter growth arrest due to a lack of wild type p53 or p21, or EGF withdrawal insensitivity (Blagosklonny et al., 2000a,b) . Therefore, it may be possible to use the window of insensitivity to DNA damage induced growth arrest to selectively target cells expressing oncogenic p53 mutants.
